Biomarker Kinetics ™ : CA-125 KELIM ™ Calculator in Ovarian Cancer & Other Biomarkers

Changes in serum tumor biomarkers may indicate treatment efficacy. Mathematical modeling allows calculation of the equations describing the longitudinal tumor biomarker time-changes. The model-based population kinetic approach is particularly relevant as it enables determination of individual kinetic profiles parameters based on a few timepoints, with limited impact of inter- and intra-individual variability of timepoints and assays.

Our tools

The team

The models were developed by Team 3 of EA3738 CICLY of Lyon University (Université Claude Bernard Lyon 1, France) and Lyon University Hospital (Hospices Civils de Lyon, France), in collaboration with the collaborative French GINECO Group, under the supervision of Prof Benoit You MD PhD. The internet site and the smartphone application were developed with the support of HCL Fondation.

More about the team >
Université Claude Bernard Lyon 1 HCL Fondation HCL

BK™ Smartphone App™ also works on your smartphone!

To add it to your home screen:

  1. 1
    Open Safari or Chrome
  2. 2
    tap the icon in Safari, or
    tap the icon in Chrome
  3. 3
    Select "Add to Home Screen"

Interested in collaboration for your datasets or your innovative drugs ? So are we!

Learn more >


Meeting for SALVOVAR project at ESMO 2023

Meeting for SALVOVAR project at ESMO 2023

The partners, investigators and investigating groups of SALVOVAR project are invited to join for a face to face meeting at Madrid on October 20th 2023 at 12:00 am for partners and 2 pm for investigators Site: Novotel Madrid Campo de las Naciones (Hotel Novotel Madrid Campo de las Naciones) - Campo De Las Naciones, C. de Ámsterdam, N° 3, 28042 Madrid, Spain Just facing the convention center

KELIM presented at ESGO 2023 !

KELIM presented at ESGO 2023 !

Biomarker-Kinetics and KELIM were presented at ESGO 2023 in a session entitled "PARPi for the better or the worse ?"

More >
Salvovar logo

Learn more about the future European clinical phase III trial SALVOVAR, where the patients with unfavorable KELIM score < 1.0 and a disease not amenable to complete interval debulking surgery after 3 to 4 cycles standard neo-adjuvant chemotherapy will be randomized to the continuation of the standard 3-weekly regimen, or a salvage regimen with weekly dose-dense carboplatin-paclitaxel

Visit website >